Search Results

Role of Phosphodiesterases in Biology and Pathology 2.0.

• Authors : Giorgi, Mauro¹ (AUTHOR) ; Pellegrini, Manuela² (AUTHOR) ; Massimi, Mara³ (AUTHOR)

Subjects: *BIOLOGY; *PHOSPHODIESTERASES; *PATHOLOGY

• Source: International Journal of Molecular Sciences. May2024, Vol. 25 Issue 10, p5339. 5p.

Record details

PDE4 Phosphodiesterases in Cardiovascular Diseases: Key Pathophysiological Players and Potential Therapeutic Targets.

• Authors : Puertas-Umbert L; Institut de Recerca Sant Pau (IR SANT PAU), 08041 Barcelona, Spain.; CIBER de Enfermedades Cardiovasculares, Instituto de Salud Carlos III, 28029 Madrid, Spain.

Subjects: Cyclic Nucleotide Phosphodiesterases, Type 4*/Cyclic Nucleotide Phosphodiesterases, Type 4*/Cyclic Nucleotide Phosphodiesterases, Type 4*/metabolism ; Cardiovascular Diseases*/Cardiovascular Diseases*/Cardiovascular Diseases*/drug therapy; Humans

• Source: International journal of molecular sciences [Int J Mol Sci] 2023 Nov 30; Vol. 24 (23). Date of Electronic Publication: 2023 Nov 30.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067

Record details

Phosphodiesterases Mediate the Augmentation of Myogenic Constriction by Inhibitory G Protein Signaling and is Negatively Modulated by the Dual Action of RGS2 and 5.

• Authors : Sun, Bo¹ (AUTHOR); Smith, Nia¹ (AUTHOR); Dixon, Alethia J¹ (AUTHOR)

• Source: Function. 2024, Vol. 5 Issue 2, p1-15. 15p.

Record details

In the Brain of Phosphodiesterases: Potential Therapeutic Targets for Schizophrenia.

• Authors : Barbagallo, Federica¹; Assenza, Maria Rita¹; Messina, Antonino²

• Source: Clinical Psychopharmacology & Neuroscience. Feb2025, Vol. 23 Issue 1, p15-31. 17p.

Record details

Targeting Striatal Glutamate and Phosphodiesterases to Control L-DOPA-Induced Dyskinesia.

• Authors : Kochoian, Brik A.¹ (AUTHOR) ; Bure, Cassandra¹ (AUTHOR) ; Papa, Stella M.^1,2 (AUTHOR)

• Source: Cells (2073-4409). Dec2023, Vol. 12 Issue 23, p2754. 21p.

Record details

Modulation of Second Messenger Signaling in the Brain Through PDE4 and PDE5 Inhibition: Therapeutic Implications for Neurological Disorders.

• Authors : Park MK; Department of Physiology, College of Medicine, Hallym University, Chuncheon 24252, Republic of Korea.; Yang HW

Subjects: Nervous System Diseases*/Nervous System Diseases*/Nervous System Diseases*/drug therapy ; Nervous System Diseases*/Nervous System Diseases*/Nervous System Diseases*/metabolism ; Cyclic Nucleotide Phosphodiesterases, Type 4*/Cyclic Nucleotide Phosphodiesterases, Type 4*/Cyclic Nucleotide Phosphodiesterases, Type 4*/metabolism

• Source: Cells [Cells] 2025 Jan 09; Vol. 14 (2). Date of Electronic Publication: 2025 Jan 09.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409

Record details

Rational Design and Optimization of Novel PDE5 Inhibitors for Targeted Colorectal Cancer Therapy: An In Silico Approach.

• Authors : Oladeji SM; Department of Chemistry, Purdue University, West Lafayette, IN 47907, USA.; Conteh DN

Subjects: Colorectal Neoplasms*/Colorectal Neoplasms*/Colorectal Neoplasms*/drug therapy ; Colorectal Neoplasms*/Colorectal Neoplasms*/Colorectal Neoplasms*/pathology ; Colorectal Neoplasms*/Colorectal Neoplasms*/Colorectal Neoplasms*/metabolism

• Source: International journal of molecular sciences [Int J Mol Sci] 2025 Feb 24; Vol. 26 (5). Date of Electronic Publication: 2025 Feb 24.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067

Record details

PDE4B promotes JNK/NLRP3 activation in the nucleus pulposus and mediates intervertebral disc degeneration.

• Authors : Xu W; Department of Orthopedics, Tongde Hospital of Zhejiang Province, Hangzhou, 310012, Zhejiang, China.; Dhar R

Subjects: NLR Family, Pyrin Domain-Containing 3 Protein*/NLR Family, Pyrin Domain-Containing 3 Protein*/NLR Family, Pyrin Domain-Containing 3 Protein*/metabolism ; NLR Family, Pyrin Domain-Containing 3 Protein*/NLR Family, Pyrin Domain-Containing 3 Protein*/NLR Family, Pyrin Domain-Containing 3 Protein*/genetics ; Cyclic Nucleotide Phosphodiesterases, Type 4*/Cyclic Nucleotide Phosphodiesterases, Type 4*/Cyclic Nucleotide Phosphodiesterases, Type 4*/metabolism

• Source: Scientific reports [Sci Rep] 2025 Feb 17; Vol. 15 (1), pp. 5739. Date of Electronic Publication: 2025 Feb 17.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Molecular Properties of Phosphodiesterase 4 and Its Inhibition by Roflumilast and Cilomilast.

• Authors : Kwak HJ; Department of Bio and Fermentation Convergence Technology, Kookmin University, Seoul 02707, Republic of Korea.; Nam KH

Subjects: Cyclopropanes*/Cyclopropanes*/Cyclopropanes*/pharmacology ; Cyclopropanes*/Cyclopropanes*/Cyclopropanes*/chemistry ; Phosphodiesterase 4 Inhibitors*/Phosphodiesterase 4 Inhibitors*/Phosphodiesterase 4 Inhibitors*/chemistry

• Source: Molecules (Basel, Switzerland) [Molecules] 2025 Feb 04; Vol. 30 (3). Date of Electronic Publication: 2025 Feb 04.Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049

Record details

PDE4B promotes ferroptosis in nucleus pulposus cells and is involved in intervertebral disc degeneration.

• Authors : Xu W; Department of Orthopedics, Tongde Hospital of Zhejiang Province, Hangzhou, 310012, Zhejiang, China.; Dhar R

Subjects: Ferroptosis*/Ferroptosis*/Ferroptosis*/drug effects ; Nucleus Pulposus*/Nucleus Pulposus*/Nucleus Pulposus*/metabolism ; Nucleus Pulposus*/Nucleus Pulposus*/Nucleus Pulposus*/pathology

• Source: Scientific reports [Sci Rep] 2025 Feb 01; Vol. 15 (1), pp. 3984. Date of Electronic Publication: 2025 Feb 01.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details